Elizabeth Repash

BT7480, a novel fully synthetic Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™) induces tumor localized CD137 agonism

N. Keen, P. Jeffrey, S. Blakemore, 2021, Journal for ImmunoTherapy of Cancer.

Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist

Rachel L. Dods, N. Keen, Jun Ma, 2021, Journal for ImmunoTherapy of Cancer.

Abstract PO077: BT7480, a novel fully synthetic tumor-targeted immune cell agonist (TICA™) induces tumor localized 4-1BB agonism

N. Keen, Jun Ma, J. Lahdenranta, 2020 .

Solving the Problem of Assessing Synergy and Antagonism for Non-Traditional Dosing Curve Compounds Using the DE/ZI Method: Application to Nrf2 Activators

P. Palenchar, A. Eggler, E. Repash, 2021, Frontiers in Pharmacology.